Logo

Geneart Posts 16 Percent Revenue Growth for Q3

Nov 11, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Geneart today reported third-quarter revenue growth of 16 percent and a sharp increase in its profit.

The German synthetic genomics firm reported revenues of €5 million ($6.9 million) for the quarter compared to €4.3 million for the third quarter of 2009.

Its earnings before interest and taxes was €135,000, up sharply from €25,000 for Q3 2009.

Geneart said that its operational performance "remained largely unaffected" by its takeover by Life Technologies' subsidiary Applied Biosystems Deutschland. The deal, which took place in May, provided Life Technologies with a 74 percent stake in Geneart for roughly €38 million.

Filed under

financial results
Thermo Fisher Scientific
Geneart
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.